

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## SoftMedx Healthcare Limited

京玖醫療健康有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

### 2025 FINAL RESULTS

The board of directors (the “Board”) of SoftMedx Healthcare Limited (the “Company”) hereby presents the audited consolidated final results of the Company and its subsidiaries (the “Group”) for the year ended 31 December 2025, together with the comparative figures for the year ended 31 December 2024, as follows:

#### CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME For the year ended 31 December 2025

	Notes	2025 HK\$'000	2024 HK\$'000
Revenue	4	68,243	54,639
Cost of goods sold		<u>(45,650)</u>	<u>(36,241)</u>
Gross profit		22,593	18,398
(Loss)/gain on debt restructuring	6	(20)	328,026
Other income, gains and losses	7	2,156	9,301
Administrative expenses		(11,069)	(9,837)
Loss on fair value changes of financial assets at fair value through profit or loss (“FVTPL”)		(2,815)	(16,613)
Finance costs	8	<u>(1,397)</u>	<u>(1,321)</u>
Profit before income tax	9	9,448	327,954
Income tax	10	<u>(2,498)</u>	<u>(1,637)</u>
<b>Profit and total comprehensive income attributable to the owners of the Company</b>		<b><u>6,950</u></b>	<b><u>326,317</u></b>
<b>Earnings per share attributable to owners of the Company</b>			
Basic and diluted	12	<b><u>HK\$0.012</u></b>	<b><u>HK\$1.0</u></b>

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION***As at 31 December 2025*

	<i>Notes</i>	<b>2025</b> <b>HK\$'000</b>	2024 HK\$'000
<b>Non-current assets</b>			
Property, plant and equipment		3	67
Right-of-use assets		512	873
Financial assets at FVTPL		—	3,915
		<u>515</u>	<u>4,855</u>
<b>Current assets</b>			
Inventories		5,438	4,781
Trade receivables	13	15,084	16,739
Prepayments and other receivables		15,513	19,519
Bank balances and cash		12,027	8,773
		<u>48,062</u>	<u>49,812</u>
<b>Current liabilities</b>			
Trade and other payables	14	4,491	13,507
Tax payable		4,030	4,677
Borrowings	15	12,099	33,113
Lease liabilities		384	363
		<u>21,004</u>	<u>51,660</u>
Net current assets/(liabilities)		<u>27,058</u>	<u>(1,848)</u>
Total assets less current liabilities		<u>27,573</u>	<u>3,007</u>
<b>Non-current liabilities</b>			
Lease liabilities		167	551
		<u>167</u>	<u>551</u>
<b>NET ASSETS</b>		<u><b>27,406</b></u>	<u><b>2,456</b></u>
<b>Capital and reserves</b>			
Share capital	16	3,048,660	3,030,660
Reserves		(3,021,254)	(3,028,204)
<b>Total equity</b>		<u><b>27,406</b></u>	<u><b>2,456</b></u>

Notes:

## 1. GENERAL INFORMATION

The Company is a public limited company incorporated in Hong Kong and its shares are listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”). The address of the registered office of the Company is located at 8th Floor, China Hong Kong Tower, 8-12 Hennessy Road, Wanchai, Hong Kong. The Group is principally engaged in the distribution of medical and healthcare equipment and products.

In the opinion of the directors of the Company, Multi Omniverse Group Limited is the immediate and ultimate holding company of the Company and its beneficial owner is Mr. Huang Jie.

## 2. APPLICATION OF NEW AND AMENDMENTS TO HKFRS ACCOUNTING STANDARDS

### 2.1 Amendments to HKFRS Accounting Standards that are mandatorily effective for the current year

In the current year, the Group has applied the following amendments to HKFRS Accounting Standards issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”) for the first time, which are mandatorily effective for the Group’s annual period beginning on 1 January 2025 for the preparation of the consolidated financial statements:

Amendments to HKAS 21	Lack of Exchangeability
-----------------------	-------------------------

The application of the amendments to an HKFRS Accounting Standard in the current year has had no material impact on the Group’s financial positions and performance for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

### 2.2 New and amendments to HKFRS Accounting Standards in issue but not yet effective

The Group has not early applied the following new and amendments to HKFRS Accounting Standards that have been issued but are not yet effective:

Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments <sup>2</sup>
Amendments to HKFRS 9 and HKFRS 7 Amendments to HKFRS 10 and HKAS 28	Contracts Referencing Nature-dependent Electricity <sup>2</sup> Sale or Contribution of Assets between an Investor and its Associate or Joint Venture <sup>1</sup>
Amendments to HKFRS Accounting Standards HKFRS 18 Amendments to HKAS 21 HKFRS 19 and its amendments	Annual Improvements to HKFRS Accounting Standards - Volume 11 <sup>2</sup> Presentation and Disclosure in Financial Statements <sup>3</sup> Translation to a Hyperinflationary Presentation Currency <sup>3</sup> Subsidiaries Without Public Accountability: Disclosure <sup>3</sup>

<sup>1</sup> Effective for annual periods beginning on or after a date to be determined.

<sup>2</sup> Effective for annual periods beginning on or after 1 January 2026.

<sup>3</sup> Effective for annual periods beginning on or after 1 January 2027.

Except for the new HKFRS Accounting Standard mentioned below, the directors of the Company anticipate that the application of all the above new and amendments to HKFRS Accounting Standards will have no material impact on the consolidated financial statements in the foreseeable future.

### HKFRS 18 Presentation and Disclosure in Financial Statements

HKFRS 18 Presentation and Disclosure in Financial Statements, which sets out requirements on presentation and disclosures in financial statements, will replace HKAS 1 Presentation of Financial Statements. This new HKFRS Accounting Standard, while carrying forward many of the requirements in HKAS 1, introduces new requirements to present specified categories and defined subtotals in the statement of profit or loss; provide disclosures on management-defined performance measures (MPMs) in the notes to the financial statements and improve aggregation and disaggregation of information to be disclosed in the financial statements. In addition, some HKAS 1 paragraphs have been moved to HKAS 8 Accounting Policies, Changes in Accounting Estimates and Errors (the title of which will be changed to "Basis of Preparation of Financial Statements" upon effective of HKFRS 18) and HKFRS 7. Minor amendments to HKAS 7 Statement of Cash Flows and HKAS 33 Earnings per Share are also made.

HKFRS 18, and amendments to other standards, will be effective for annual periods beginning on or after 1 January 2027, with early application permitted. HKFRS 18 requires retrospective application with specific transition provisions. The application of the new standard is not expected to have significant impact on the financial performance and positions of the Group in terms of recognition and measurement. The directors of the Company are in the process of assessing the detailed impact on the consolidated financial statements.

### 3. BASIS OF PREPARATION

The consolidated financial statements have been prepared in accordance with HKFRS Accounting Standards, which includes all Hong Kong Financial Reporting Standards (“HKFRS”), Hong Kong Accounting Standards (“HKAS”) and HK (IFRIC) Interpretations, HK Interpretations and HK (SIC) Interpretations (collectively referred to as “Interpretations”), issued by the HKICPA. For the purpose of preparation of the consolidated financial statements, information is considered material if such information is reasonably expected to influence decisions made by primary users. In addition, the consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on The Stock Exchange (the “Listing Rules”) and by the Hong Kong Companies Ordinance.

The consolidated financial statements are presented in Hong Kong dollars (“HK\$”), which is the same as the functional currency of the Company, and all values are rounded to the nearest thousand except when otherwise indicated.

Trading in the shares of the Company had been suspended since 27 November 2017. Resumption of trading in the shares of the Company is subject to fulfilment of the following resumption guidance imposed by the Stock Exchange:

- (i) publication of all outstanding financial results in accordance with the Listing Rules;
- (ii) demonstration of the Company’s compliance with Rule 13.24 of the Listing Rules;
- (iii) re-compliance with Rules 3.10(1) and 3.21 of the Listing Rules; and
- (iv) announcement of all material information for the Company’s shareholders and other investors to appraise the Company’s position.

As set out in the announcement of the Company dated 31 October 2025, trading in the shares of the Company on the Stock Exchange has resumed on 4 November 2025 following the satisfaction of the above resumption guidance.

### 4. REVENUE

An analysis of revenue as follows:

#### (i) Disaggregation of revenue from contracts with customers

	2025 <i>HK\$ '000</i>	2024 <i>HK\$ '000</i>
<b>Types of goods or service</b>		
Medical and well-being business		
- Distribution of medical and healthcare equipment and products	<u>68,243</u>	<u>54,639</u>
<b>Geographical market</b>		
Hong Kong	<u>68,243</u>	<u>54,639</u>
<b>Time of revenue recognition</b>		
A point in time basis	<u>68,243</u>	<u>54,639</u>

#### (ii) Performance obligations for contracts with customers

For distribution of medical and healthcare equipment and products to customers, revenue is recognised when control of the goods has transferred to the customer, being at the point the goods are delivered to and accepted by the customer. Delivery occurs when the goods have been shipped to a customer’s specific location.

### 5. SEGMENT REPORTING

The Group’s reportable and operating segments under HKFRS 8 are based on the information reported to the executive Directors, the chief operating decision maker of the Group, for the purposes of resource allocation and assessment of segment performance, which focuses on the types of goods or services delivered or provided. The management of the Group monitors the results of the Group’s operating segments separately for the purpose of making decisions about resources allocation and performance assessment. Segment performance is evaluated based on reportable segment results, which is measure of adjusted profit or loss before income tax. In accordance with the way in which information is reported internally to the chief operating decision maker for the purpose of resource allocation and performance assessment, the Group has one reportable operating segment i.e. the medical and well-being business for distribution of medical and healthcare equipment and products. The adjusted profit or loss before income tax is measured consistently with the Group’s profit or loss before income tax except that unallocated other income, gains and losses, loss/gain on debt restructuring, loss on fair value changes on financial assets at FVTPL, finance costs and corporate expenses are excluded from such measurement. Segment assets exclude unallocated head office and corporate assets that are managed on a group basis. Segment liabilities exclude borrowings and unallocated head office and corporate liabilities that are managed on a group basis.

- (i) The following summary describes the Group's reportable segments:

**For the year ended 31 December 2025**

	Medical and well-being business <i>HK\$'000</i>	Total <i>HK\$'000</i>
External sales and reportable segment revenue	<u>68,243</u>	<u>68,243</u>
Reportable segment results	<u>15,595</u>	15,595
Unallocated corporate income and expenses		(5,337)
Unallocated finance costs		<u>(810)</u>
Profit before income tax		<u>9,448</u>
Reportable segment assets	48,150	48,150
Unallocated assets		427
Total assets		<u>48,577</u>
Reportable segment liabilities	20,117	20,117
Unallocated liabilities		<u>1,054</u>
Total liabilities		<u>21,171</u>
Other information:		
Depreciation of right-of-use-assets	361	361
Depreciation of property, plant and equipment	64	<u>64</u>

**For the year ended 31 December 2024**

	Medical and well-being business <i>HK\$'000</i>	Total <i>HK\$'000</i>
External sales and reportable segment revenue	<u>54,639</u>	<u>54,639</u>
Reportable segment results	<u>12,265</u>	12,265
Unallocated corporate income and expenses		316,150
Unallocated finance costs		<u>(461)</u>
Profit before income tax		<u>327,954</u>
Reportable segment assets	50,372	50,372
Unallocated assets		4,295
Total assets		<u>54,667</u>
Reportable segment liabilities	31,703	31,703
Unallocated liabilities		<u>20,508</u>
Total liabilities		<u>52,211</u>
Other information:		
Addition to right-of-use assets	1,084	1,084
Depreciation of right-of-use-assets	421	421
Depreciation of property, plant and equipment	171	<u>171</u>

- (ii) Revenue from major products and services

The following is an analysis of the Group's revenue from its major products and services:

	2025 <i>HK\$'000</i>	2024 <i>HK\$'000</i>
Income from distribution of medical and healthcare equipment and products	<u>68,243</u>	<u>54,639</u>

- (iii) Geographical information

The Group's operation is located in Hong Kong. The Group's revenue from external customers is all from Hong Kong and non-current assets of the Group are located in Hong Kong.

## 6. (LOSS)/GAIN ON DEBT RESTRUCTURING

During the year ended 31 December 2023, the Company had conducted a debt restructuring by way of scheme of arrangement between the Company and its creditors pursuant to Sections 670 and 673 of the Companies Ordinance (Cap 622 of the laws of Hong Kong) (the “Scheme”) in order to restore the Group’s financial and business positions to normality. The Scheme was sanctioned by the High Court of the Hong Kong Special Administrative Region and registered on the Companies Registry on 18 December 2023. Gain on debt restructuring from derecognition of liabilities of approximately HK\$328,026,000 was recorded upon the settlement made during the year ended 31 December 2024. Due to the resumption of trading in the shares of the Company on 4 November 2025, an additional of approximately HK\$20,000 was recorded during the year ended 31 December 2025 in accordance with the Scheme.

## 7. OTHER INCOME, GAINS AND LOSSES

	2025 <i>HK\$’000</i>	2024 <i>HK\$’000</i>
Interest income on bank balances	68	188
Exchange gains	–	8,044
Waiver of loan interest	1,462	–
Others	626	1,069
	<u>2,156</u>	<u>9,301</u>

## 8. FINANCE COSTS

	2025 <i>HK\$’000</i>	2024 <i>HK\$’000</i>
<b>Interest expenses on:</b>		
Bank and other borrowings	1,355	1,285
Lease liabilities	42	36
	<u>1,397</u>	<u>1,321</u>

## 9. PROFIT BEFORE INCOME TAX

Profit before income tax is arrived at after charging:

	2025 <i>HK\$’000</i>	2024 <i>HK\$’000</i>
Depreciation of property, plant and equipment	64	171
Depreciation of right-of-use assets	361	421
	<u>425</u>	<u>592</u>
Auditors’ remuneration	1,000	1,000
Cost of inventories recognised as expenses	45,650	36,241
Staff costs and other benefits (including Directors’ emolument)		
- Staff salaries	4,199	3,590
- Provident fund contributions	109	176
	<u>1,000</u>	<u>1,000</u>

## 10. INCOME TAX

The amount of income tax in the consolidated statement of profit or loss and other comprehensive income represents:

	2025 <i>HK\$’000</i>	2024 <i>HK\$’000</i>
Current tax – Hong Kong Profits Tax	<u>2,498</u>	<u>1,637</u>

Under the two-tiered profits tax rates regime of Hong Kong Profits Tax, the first HK\$2 million of profits of the qualifying group entity is taxed at 8.25%, and profits above HK\$2 million are taxed at 16.5%. The profits of the group entities not qualifying for the two-tiered profits tax rates regime continue to be taxed at a flat rate of 16.5%. Accordingly, the Hong Kong Profits Tax of the qualifying group entity is calculated at 8.25% on the first HK\$2 million of the estimated assessable profits and at 16.5% on the estimated assessable profits above HK\$2 million.

## 11. DIVIDEND

The Directors do not recommend any dividend for the year ended 31 December 2025 (2024: Nil).

## 12. EARNINGS PER SHARE

The calculation of the basic and diluted earnings per share attributable to the owners of the Company is based on the following data:

	2025 <i>HK\$'000</i>	2024 <i>HK\$'000</i>
Profit for the year attributable to owners of the Company	<u>6,950</u>	<u>326,317</u>

No diluted earnings per share for both 2025 and 2024 were presented as there was no potential ordinary share in issue for both 2025 and 2024.

	2025 <i>'000</i>	2024 <i>'000</i>
Weighted average number of ordinary shares for the purpose of basic earnings per share	<u>577,544</u>	<u>326,037</u>

## 13. TRADE RECEIVABLES

	2025 <i>HK\$'000</i>	2024 <i>HK\$'000</i>
Trade receivables	15,084	16,739
Less: Impairment allowance	<u>—</u>	<u>—</u>
	<u>15,084</u>	<u>16,739</u>

The Group's trading terms with its customers are mainly on credit. The credit period is generally 90 days (2024: 90 days). Each customer has a maximum credit limit. The Group seeks to maintain strict control over its outstanding receivables to minimise credit risk. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivables balances. Trade receivables are non-interest-bearing.

The following is an aged analysis of the trade receivable based on the invoice date, at the end of the reporting period, which approximated the respective revenue recognition dates:

	2025 <i>HK\$'000</i>	2024 <i>HK\$'000</i>
0 – 30 days	5,264	3,362
31 – 90 days	7,078	8,149
91 – 180 days	2,582	4,789
Over 181 days	<u>160</u>	<u>439</u>
	<u>15,084</u>	<u>16,739</u>

## 14. TRADE AND OTHER PAYABLES

	2025 <i>HK\$'000</i>	2024 <i>HK\$'000</i>
Trade payables	2,948	10,081
Trade deposit	201	270
Accrued wage and staff benefit	456	204
Other payables and accruals	<u>886</u>	<u>2,952</u>
	<u>4,491</u>	<u>13,507</u>

The ageing analysis of the trade payables, based on invoice date, is as follows:

	2025 <i>HK\$'000</i>	2024 <i>HK\$'000</i>
0 – 30 days	1,554	–
31 – 90 days	1,054	4,627
91 – 180 days	340	5,454
	<u>2,948</u>	<u>10,081</u>

The average credit period on purchases of goods is 90 days.

## 15. BORROWINGS

	2025 <i>HK\$'000</i>	2024 <i>HK\$'000</i>
Bank loans ( <i>note (a)</i> )	12,099	14,436
Loans from independent third parties ( <i>note (b)</i> )	–	18,677
	<u>12,099</u>	<u>33,113</u>
Analysed into:		
Repayable within one year or on demand	12,099	33,113
Repayable within a period of more than one year	–	–
	<u>12,099</u>	<u>33,113</u>
Unsecured	<u>12,099</u>	<u>33,113</u>

Notes:

- (a) The amount represented bank loans with aggregate principal of HK\$12,099,000 (2024: HK\$14,436,000) as at 31 December 2025 with interest rates ranging from 2.6% per annum over one-month-HIBOR to 2.5% per annum below the prime lending rate.
- (b) The loans with aggregate principal of HK\$18,025,000 as at 31 December 2024 born an interest rate at 5% and was settled by the issuance of new shares of the Company in 2025 as a result of the loan conversions (*note 16*).

## 16. SHARE CAPITAL

	Number of shares <i>'000</i>	Amount <i>HK\$'000</i>
Issued and fully paid:		
As at 31 December 2024 and 1 January 2025	326,037	3,030,660
Allotment of shares – Conversion of loans from independent third parties ( <i>Note</i> )	1,800,000	18,000
	<u>2,126,037</u>	<u>3,048,660</u>
As at 31 December 2025	<u>2,126,037</u>	<u>3,048,660</u>

Note: 1,800,000,000 conversion shares have been allotted and issued on 11 November 2025 as a result of the loan conversion in accordance with the terms and conditions of the restructuring agreements as set out in the circular of the Company dated 30 November 2023.

As the restructuring agreements specified a fixed number of shares (1,800,000,000 shares) be issued (at the conversion price of HK\$0.01 per share) upon the conversion of the loan, the conversion right was regarded as an equity instrument and changes in its fair value are not recognised in the financial statements in accordance with HKAS 32.

## 17. EVENTS AFTER THE REPORTING PERIOD

In connection with the Scheme (as detailed in note 6), the Group had the following significant event after the end of the reporting period:

Subject to the approval of the Shareholders at the extraordinary general meeting of the Company to be held on 30 March 2026, 16,301,841 new shares of the Company will be allotted and issued to the scheme creditors (defined in the announcement dated 10 March 2026) under the Scheme. Details are set out in the announcement of the Company dated 10 March 2026.

## MANAGEMENT DISCUSSION AND ANALYSIS

### BUSINESS OVERVIEW

The Group is principally engaged in medical and well-being business for distribution of medical and healthcare equipment and products. The Group's revenue comprises income from sales of devices and consumable products and provision of supportive services. Through continuous efforts, the Group has become the authorized distributor for ten equipment providers in 2025.

The medical devices market in Hong Kong has been growing since 2022 and is projected to experience consistent growth rate between 2025 and 2029 and the annual growth rate will remain at 7.3% in 2029. This performance is driven by factors such as local special circumstances, consumer preference for high quality and latest technology, and the well-developed local healthcare system. Given the Group's significantly improved financial position, the Group now has the resources to further invest and expand its business and expects the sales revenue and sales volume will continue to grow in the coming years. Particularly, the Group will keep expanding its product sources and product offerings and strengthening its financial resources to better position itself to tender suitable projects in the public sector. The Group is committed to leveraging its industry experience, customer relationships, technical proficiency, and significantly improved financial position to keep expanding its product sources and product offerings, while maintaining its market position and delivering high quality and reliable services to customers.

### REVIEW OF FINANCIAL RESULTS

#### Revenue and gross profit

The Group's revenue for the year ended 31 December 2025 increased by 25% to HK\$68.2 million (2024: HK\$54.6 million). Such increase was mainly attributable to the Group's continued efforts in obtaining new product sources to broaden its product offerings. The gross profit of the Group increased by 23% to HK\$22.6 million (2024: HK\$18.4 million) whilst gross profit margin maintained at a similar level of 33.1% (2024: 33.7%).

#### Profit for the year

The Group recorded a consolidated profit attributable to the owners of the Company of HK\$7.0 million for the year ended 31 December 2025 as compared to HK\$326.3 million for the year ended 31 December 2024, mainly attributable to the following factors:

*Decrease in loss arising from change in fair value of financial assets at fair value through profit and loss*

The fair value of listed equity investments is determined by reference to the quoted market bid prices on The Stock Exchange of Hong Kong Limited ("Stock Exchange"). During the year ended 31 December 2025, the Group recognised a fair value loss of HK\$2.8 million, compared to loss of HK\$16.6 million for the year ended 31 December 2024. No dividends were received from such listed equity investment during the year.

*Absence of gain on debt restructuring and decrease in other income*

As the Group settled its borrowings under the scheme of arrangement in 2024, no gain on debt restructuring was recorded in 2025.

Due to the absence of exchange gain after settlement of the Group's borrowings dominated in Japanese Yen in 2024, the Group's other income decreased to HK\$2.2 million for the year ended 31 December 2025, as compared to HK\$9.3 million for the year ended 31 December 2024.

#### Liquidity, Financial Resources and Capital Structure

During the year ended 31 December 2025, the Group financed its operations by internally generated cash flow and bank borrowings. As a result of issuance of 1,800 million new shares of the Company for settlement of loans and the net profit attributed during the year, the Group's consolidated net assets as at 31 December 2025 increased to HK\$27.4 million (2024: HK\$2.5 million) with total asset and total liabilities amounted to HK\$48.6 million (2024: HK\$54.7 million) and HK\$21.1 million (2024: HK\$52.2 million) respectively. As at 31 December 2025, the Group had current assets HK\$48.1 million (2024: HK\$49.8 million), comprising cash and bank balances of HK\$12.0 million (2024: HK\$8.8 million), and current liabilities HK\$21.0 million (2024: HK\$51.7 million). As at 31 December 2025, the Group's total borrowings amounted to HK\$12.1 million (2024: HK\$33.1 million) and its liquidity ratio (calculated based on the Group's total assets to total liabilities) was 2.30 (2024: 1.05).

During the year ended 31 December 2025, the Group's net cash inflow from operating activities amounted to HK\$5.4 million (2024: HK\$3.9 million), net cash inflow from investing activities amounted to HK\$1.2 million (2024: HK\$0.2 million) and net cash outflow from financing activities amounted to HK\$3.3 million (2024: HK\$3.4 million). Accordingly, the Group had a net cash inflow of HK\$3.3 million (2024: HK\$0.7 million).

As a result of the above-mentioned issuance of 1,800 million new shares of the Company, the Company's total issued shares as at 31 December 2025 increased to 2,126,036,828 shares (2024: 326,036,828 shares) with its issued share capital increased to HK\$3,048,660,000 (2024: HK\$3,030,660,000).

### **Corporate Development and Future Prospects**

Looking ahead, challenges from the disruptive changes in the business environment following the COVID-19 pandemic, together with the added complexity of the wars in Ukraine and the Middle East, global trade tensions and the geopolitical impact on the worldwide economic landscape and supply chains, will continue to affect the global and local economies and may affect the Group's business operations. The Company, with the resumption of trading in its shares in November 2025, will strive to harness its listing platform to emerge stronger to navigate this very challenging landscape and work towards a brighter future for all stakeholders. The Company will remain focused on the organic growth of its principal businesses through improvement on business model and process, increased market penetration, expansion in product sources and range and widening customer reach. On the other hand, the challenges and uncertainty in the current economic environment may result in more opportunities in the healthcare sector coming to market. The Company, while adopting the newly established policies in ensuring disciplined execution of prudent financial, liquidity and cash flow management, will continue to seek new business opportunities with a view to achieving earning growth and enhancing the long-term value of all of its stakeholders.

### **Purchase, Sale or Redemption of the Company's Listed Securities**

Neither the Company nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities during the year ended 31 December 2025.

### **Events after the Reporting Period**

Details of the events after the reporting period are set out in note 17 to the consolidated financial statements..

### **MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS**

All Directors have confirmed that they had complied with the required standards under the Listing Rules regarding securities transactions by directors during the year ended 31 December 2025.

### **COMPLIANCE WITH CODE ON CORPORATE GOVERNANCE PRACTICES**

The audit committee of the Board is satisfied that the Company has throughout the year complied with all applicable code provisions of the Corporate Governance Code set out in Appendix C1 of the Listing Rules other than the vacancy of the office of the chief executive and chairman of the Board. The Board will keep identifying a suitable candidate with suitable skills and experience to fill the post.

### **REVIEW OF ANNUAL RESULTS BY AUDIT COMMITTEE**

The audit committee has reviewed the Group's annual results for the year ended 31 December 2025, including the accounting principles and practices adopted by the Group.

### **SCOPE OF WORK OF THE AUDITOR**

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the year ended 31 December 2025 set out in this announcement have been agreed by the Group's auditor, Rongcheng (Hong Kong) CPA Limited ("Rongcheng", formerly known as "CL Partners CPA Limited"), to the amounts set out in the audited consolidated financial statements of the Group for the year as approved by the Board on 27 March 2026. The work performed by Rongcheng in this respect did not constitute an assurance engagement and consequently no opinion or assurance conclusion has been expressed by Rongcheng in this announcement.

## **PUBLICATION OF ANNUAL RESULTS AND ANNUAL REPORT**

This announcement is published on the websites of the Company ([www.648.com.hk](http://www.648.com.hk)) and the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)). The 2025 annual report of the Company will be despatched to the shareholders and posted on the websites of the Company and the Stock Exchange in due course.

For and on behalf of the board of  
**SoftMedx Healthcare Limited**  
Lam Sung Him Gaston  
*Company Secretary*

Hong Kong, 27 March 2026

*As at the date of this announcement, the Board comprises Mr. Lin Pinzhuo as executive director; and Mr. Ngok Ho Wai, Ms. Tang Cuihuen and Mr. Yiu Chun Wing as independent non-executive directors.*